NANEMIAR Holds Its Third Consortium Meeting and General Assembly in the Netherlands

  • 10/07/2025

The international consortium of the European project NANEMIAR (Nanomedicine Approach to Normalize Erythrocyte Maturation in Congenital Anemia by Messenger RNA) hold successfully its 3rd Consortium Meeting and 3rd General Assembly on July 7–8, 2025, at the BioMatTech Campus in Nijmegen, the Netherlands. This ambitious project is funded by the Horizon Europe program and involves key partners from Spain (FFIS-IMIB), France (CNRS), and the Netherlands (MERCURNA).

Throughout the two-day event, intensive working sessions focused on the project's work packages, addressing topics ranging from the development and pharmaceutical application of therapeutic mRNA to communication strategies and exploitation of results.

In addition, participants had the opportunity to visit to RIBOPRO’s lab facilities, located at Pivot Park in Oss, a leading biotechnology company in the Netherlands.

 

Source of information: NANEMIAR Consortium

 


 


 


 

"NANEMIAR project is funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them."